Important new or changed information affecting administration,  stability or compatibility. We recommend printing and replacing these pages in your hard copy of  AIDH 9.

Albumin March 2024

Ampicillin September 2024

Benzathine benzylpenicllin June 2024

Beriplex P/N (replaces Prothrombinex -VF) June 2024

Imipenem-cilastatin December 2023

Dacarbazine December 2023

Oxycodone December 2023

Oxytocin September 2024

Plitidpesin December 2023

Suxamethonium June 2024

Ustekinumab September 2024

These new medicine monographs are added to AIDH 9 online. These monographs are not included in the print copy of AIDH 9, including reprints. 

Andexanet alfa

Beriplax P/N

Bimekizumab

Clozapine

Difelikefalin

Dostarlimab

Enfortumab vedotin

Faricimab

Fosnetupitant & palonosetron

Lenacapavir

Nirsevimab

Nivolumab & relatlimab

Progesterone

Sebelipase alfa

Spesolimab

Tebentafusp

Teclistamab

Tirzepatide

Vosoritide

September 2024

New monographs for bimekizumab, spesolimab, tebentafusp, and teclistamab

Updated availability information for aciclovir, gentamicin, metoclopramide, and natalizumab

Updated preparation information for ustekinumab

Updated administration advice for ampicillin, and oxytocin

July 2024

Summary of glucose 5 % compatibility information to assist with managing the anticipated shortage of IV fluids

June 2024

New monographs for Beriplex P/N (Prothrombin complex), clozapine, nirsevimab, sebelipase alfa

Updated availability information for benzathine benzylpenicillin, sugammadex

Updated stability information for buprenorphine subcut depot, filgrastim and lipegfilgrastim, rocuronium

Updates to labetalol, lorazepam, suxamethonium in response to user feedback

Minor editorial updates to Prothrombinex-VF and vancomycin

March 2024

New monographs for enfortumab vedotin, fosnetupitant and palonosetron (Akynzeo IV), nivolumab and relatlimab (Opdualag), progesterone, and tirzepatide.

Updated availability information for adalimumab, albumin, palifermin, and zoledronic acid.

Updated monitoring information for calcium salts

New CoPAT stability information for aztreonam, and cefiderocol

Updated administration advice for cetuximab

Minor editorial updates to ceftriaxone, and palonosetron

December 2023

Medicines shortage advice for benzathine benzylpenicillin

New monographs for andexanet alfa, difelikefalin, dostarlimab, faricimab, lenacapavir, and vosoritide

Updated availability information for carboprost, daptomycin, and pemetrexed

Medicine shortages availability advice for dipyridamole, fludarabine, and mycobacterium bovis

Updated stability information for chorionic gonadotropin, dacarbazine, fulvestrant, natalizumab, and omalizumab

New compatibility information for oxycodone (Hartmann’s)

Addition of infusion equipment requirements for plitidepsin

Clarification of diluent for sodium valproate in status epilepticus

Clarification of soy as source of lecithin in benzathine benzylpenicillin (Bicillin-LA)

Updates to imipenem-cilastatin, and isavuconazole in response to user feedback

Summary of medicines requiring non-PVC and/or DEHP-free containers and infusion sets.

September 2023

Aciclovir (addition of powder presentation)

Phenylephrine (addition of Accord brand)

Aciclovir (powder presentation, S19A product)

Adamilumamb (biosimilars)

Albumin (Alburex 5% replaces Albumem 4%)

Ampicillin (administration)

Aztreonam (CoPAT stability)

Benzathine benzylpenicillin (medicines shortage advice)

Beriplex P/N (replaces Prothrombinex-VF)

Buprenorphine subcut depot (stability)

Calcium chloride and calcium gluconate (monitoring)

Carboprost (addition of Australian-registered products)

Cefiderocol (CoPAT stability)

Ceftriaxone (link to ANMF)

Cetuximab (administration)

Chorionic gonadotropin (stability)

Dacarbazine (stability)

Daptomycin (new products)

Dipyridamole (S19A products)

Filgrastim and lipegfilgrastim (stability)

Fludarabine (19A products)

Fulvestrant (stability)

Gentamicin (new products)

Imipenem-cilastatin  (preparation)

Isavuconazole (prodrug equivalence)

Labetalol (administration advice)

Lorazepam (administration advice)

Metoclopramide (new products)

Mycobacterium bovis (S19A products)

Natalizumab (stability, subcutaneous formulation)

Omalizumab (stability)

Oxycodone (compatibility and stability)

Oxytocin (administration)

Palifermin (presentation)

Palonosteron (hypersensitivity reports)

Pemetrexed (concentrated solution)

Phenylephrine (new product)

Plitidepsin (clarification of container and infusion-set requirements)

Rocuronium (stability)

Sodium valproate (compatibility)

Sugammadex (new products)

Suxamethonium (compatibility)

Ustekinumab (preparation)

Zoledronic acid (new product, administration)